Stratification of prognosis of triple-negative breast cancer patients using combinatorial biomarkers

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Yue, Yong ^a   Astvatsaturyan, Kristine ^a   Cui, Xiaojiang ^a   Zhang, Xiao ^a   Fraa, Benedick ^a   Bose, Shikha ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER; VASCULOTROPIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; AGED; BREAST; FEMALE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84960976823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149661     Document Type: Article

References (25)

1. Diaz L. K., Cryns V. L., Symmans W. F., Sneige N. Triple negative breast carcinoma and the basal phenotype: from expreion profiling to clinical practice. Advances in Anatomic Pathology, 2007, 14(6), 419-30. doi:10.1097/PAP.0b013e3181594733 PMID: 18049131.
2. Hudis C. A, Gianni L. Triple-negative breast cancer: An unmet medical need. The Oncologist, 2011, 16 Suppl 1, 1-11. doi: 10.1634/theoncologist.2011-S1-01 PMID: 21278435.
3. Bidard F. C., Conforti R., Boulet T., Michiels S., Delaloge S., André F. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 "triple-negative" breast cancers. Annals of Oncology, 2007, 18(7), 1285-6. doi:10.1093/annonc/mdm360 PMID: 17675400.
4. Cheang M. C. U., Voduc D., Bajdik C., Leung S., McKinney S., Chia S. K., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical Cancer Research, 2008, 14(5), 1368-76. doi:10.1158/1078-0432.CCR-07-1658 PMID: 18316557.
5. Prat A., Adamo B., Cheang M. C, Anders C., Carey L. A., Perou CM. Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers. Oncologist., 2013, 18(2), 122-33.
6. Chen X, Li J, Gray WH, Lehmann BD, Bauer JA, Shyr Y, et al. TNBC type: A subtyping tool for triplenegative breast cancer. Cancer Inform, 2012; 11:147-56. doi:10.4137/CIN.S9983 PMID: 22872785.
7. Weigelt B., Pusztai L., Ashworth A., Reis-Filho J. S. Challenges translating breast cancer gene signatures into the clinic. Nature Reviews Clinical Oncology, 2012, 9(1), 58-64. doi:10.1038/nrclinonc.2011.125.
8. Mackay A., Weigelt B., Grigoriadis A., Kreike B., Natrajan R., A'Hern R., et al.. Microarray-based cla discovery for molecular claification of breast cancer: Analysis of interobserver agreement Journal of the National Cancer Institute, 2011, 103(8), 662-73. doi:10.1093/jnci/djr071 PMID: 21421860.
9. Viale G., Rotmensz N., Maisonneuve P., Bottiglieri L., Montagna E., Luini A., et al. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Research and Treatment, 2009, 116(2), 317-28. doi:10.1007/s10549-008-0206-z PMID: 18839307.
10. Zhang M., Zhang X., Zhao S., Wang Y., Di W., Zhao G., et al. Prognostic value of survivin and EGFR protein expreion in triple-negative breast cancer (TNBC) patients. Targeted Oncology, 2013, 2. doi:10.1007/s11523-013-0300-y.
11. Thike A. A., Iqbal J., Cheok P. Y., Chong A. P. Y., Tse G. M.-K., Tan B., et al. Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. The American Journal of Surgical Pathology, 2010, 34(7), 956-64. doi:10.1097/PAS.0b013e3181e02f45 PMID: 20495445.
12. Kutomi G. Clinicopathological Characteristics of Basal Type Breast Cancer in Triple-Negative Breast Cancer. Journal of Cancer Therapy, 2012, 03(05), 836-840. doi:10.4236/jct.2012.325106.
13. Rakha E. A, Reis-Filho J. S., Ellis I. O. Combinatorial biomarker expreion in breast cancer. Breast Cancer Research and Treatment, 2010, 120(2), 293-308. doi:10.1007/s10549-010-0746-x PMID: 20107892.
14. McShane LM, Altman DG, Sauerbrei W, Taube S, Gion M., Clark G. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat, 2006, 100:229-235. doi:10.1007/s10549-006-9242-8 PMID: 16932852.
15. Adams H, Tzankov A, Lugli A, Zlobec I. New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma. J Clin Pathol, 2009, 62: 986-997. doi:10.1136/jcp.2008.059063 PMID: 18977805.
16. Keam B., Im S.-A., Lee K.-H., Han S.-W., Oh D.-Y., Kim J. H., et al. Ki-67 can be used for further claification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Research, 2011, 13(2), R22. doi:10.1186/bcr2834 PMID: 21366896.
17. Blanche P., Dartigues J.-F., Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Statistics in Medicine, 2013, 32(30), 5381-97. doi:10.1002/sim.5958 PMID: 24027076.
18. Kang M. H., Go S.-I., Song H.-N., Lee a, Kim S.-H., Kang J.-H., et al. The prognostic impact of the neutrophil- to-lymphocyte ratio in patients with small-cell lung cancer. British Journal of Cancer, 2014, 111 (3), 452-60. doi:10.1038/bjc.2014.317 PMID: 24921916.
19. Hudis C, Barlow W, Costantino J, Gray RJ, Pritchard KI, Chapman JA, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol. 2007; 25:2127-2132 PMID: 17513820.
20. Corder G., Foreman D. Nonparametric Statistics for Non-Statisticians. Hoboken: John Wiley & Sons. 2009, pp. 99-105.
21. Bradburn M. J., Clark T. G., Love S. B., Altman D. G. Survival analysis Part III: multivariate data analysis- choosing a model and aeing its adequacy and fit. British Journal of Cancer, 2003, 89(4), 605-11. doi:10.1038/sj.bjc.6601120 PMID: 12915864.
22. Aike H. A. I. A New Look at the Statistical Model Identification. IEEE Trans. Auto. Control, AC, 1974, 19 (6), 716-23.
23. Burnham K. P.; Anderson D. R. Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach ( 2nd ed.), Springer-Verlag, 2002, ISBN0-387-95364-7.
24. Zlobec I., Steele R., Terracciano L., Ja J. R., Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progreion and survival in colorectal cancer. Journal of Clinical Pathology, 2007, 60(10), 1112-6. doi:10.1136/jcp.2006.044537 PMID: 17182662.
25. Takahashi H., Kurishima K., & Ishikawa H. Optimal Cutoff Points of CYFRA21-1 for Survival Prediction in Non-small Cell Lung Cancer Patients Based on Running Statistical Analysis, Anticancer Res. 2010, 30, 3833-3837. PMID: 20944179.